Fast track — Research LettersIntralesional injection of herpes simplex virus 1716 in metastatic melanoma
References (5)
- et al.
Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence
J Gen Virol
(1991) - et al.
Cell type and cell state determine differentiated in vitro growth of nonneurovirulant ICP34.5-negative herpes simplex virus
J Gen Virol
(1994)
There are more references available in the full text version of this article.
Cited by (143)
Advances in adoptive T-cell therapy for metastatic melanoma
2023, Current Research in Translational MedicineTGF-β Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma
2017, Molecular Therapy OncolyticsCitation Excerpt :HSV1716 is an oHSV that is attenuated through deletion of the herpes neurovirulence factor ICP34.5. The loss of this factor, which normally counteracts the interferon and protein kinase R (PKR)-mediated shutdown of virus gene translation, restricts HSV1716 replication to cells in which these pathways are disabled (i.e., tumor cells).23 HSV1716 exhibits lytic activity against a wide variety of cancers and has been safely administered in multiple clinical trials, including an on-site trial for pediatric patients.24,25
Viral oncolytic immunotherapy in the war on cancer: Infection control considerations
2019, Infection Control and Hospital EpidemiologyNon-Surgical Treatment Methodologies and Prevention for Malignant Melanoma
2024, Advancements in Life SciencesEffects on exocytosis by two HSV-1 mutants unable to block autophagy
2023, Journal of Virology
Copyright © 2001 Elsevier Ltd. All rights reserved.